// App-Quantinova.ai

e17046 : PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Researchers

Presenter

  • Mohammad O. Atiq

Principal Investigators

  • Fatima Karzai

  • Munjid Al Harthy

  • Gang Chen

  • Marijo Bilusic

  • David James VanderWeele

  • Elias Bin Aris Chandran

  • Lisa M. Cordes

  • Helen Owens

  • Anna Couvillon

  • Amy Hankin

  • Monique Williams

  • William Douglas Figg

  • Peter L. Choyke

  • Liza Lindenberg

  • Esther Mena

  • William L. Dahut

  • James L. Gulley

  • Ravi Amrit Madan

Medical Centers

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • National Cancer Institute, Bethesda, MD

  • Radiation Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Northwestern University, Chicago, IL

  • Waikato District Health Board, Hamilton, New Zealand

  • Clinical Pharmacology Program, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD

  • Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Locations

  • United States

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

  • Folate Hydrolase 1

Drug/Treatment

  • 18F-DCFPyL

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02649855

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved